5 July 2022
EMA/581764/2022
EMEA/H/C/005298

Public statement

Senstend (lidocaine / prilocaine)

Withdrawal of the marketing authorisation in the European Union

On 24 June, the European Commission withdrew the marketing authorisation for Senstend (lidocaine / prilocaine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Plethora Pharma Solutions Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Senstend was granted marketing authorisation in the EU on 14 November 2019 for the treatment of primary premature ejaculation. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU since its approval in 2019.

Senstend was a duplicate application to Fortacin, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Fortacin.

The European Public Assessment Report (EPAR) for Senstend will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union